Issues in assessing products for the treatment of hemophilia - the intersection between efficacy, economics, and ethics.

about

Emerging drugs for the treatment of hemophilia A and B.Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia

P2860

Q38933707-6C08FD6B-1D8E-410B-870A-823D0B7E0F5D Q58701325-60DDFC10-4904-4D84-B179-5088D81F2F2C

P2860

Issues in assessing products for the treatment of hemophilia - the intersection between efficacy, economics, and ethics.

Item

http://www.wikidata.org/entity/Q35766551

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Issues in assessing products f ...... ficacy, economics, and ethics.

@ast

Issues in assessing products f ...... ficacy, economics, and ethics.

@en

type

Item

label

Issues in assessing products f ...... ficacy, economics, and ethics.

@ast

Issues in assessing products f ...... ficacy, economics, and ethics.

@en

prefLabel

Issues in assessing products f ...... ficacy, economics, and ethics.

@ast

Issues in assessing products f ...... ficacy, economics, and ethics.

@en

P1476

Issues in assessing products f ...... fficacy, economics, and ethics

@en

P2093

Brian O'Mahony

http://www.w3.org/2001/XMLSchema#string

Declan Noone

http://www.w3.org/2001/XMLSchema#string

Josephine Cassar

http://www.w3.org/2001/XMLSchema#string

Steffen Schlenkrich

http://www.w3.org/2001/XMLSchema#string

Uwe Schlenkrich

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery

Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B

Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease

Using N-of-1 trials to improve patient management and save costs

Evidence based medicine: what it is and what it isn't

The environment and disease: association or causation? 1965.

Gene therapy for hemophilia

Does the FDA have the authority to trump the Declaration of Helsinki?

N-of-1 trials of expensive biological therapies: a third way?

Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels.

P304

185-195

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.2147/JBM.S79091

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Albert Farrugia

P577

2015-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26124687

http://www.w3.org/2001/XMLSchema#string

P921

research ethics

hemophilia

P932

4476485

http://www.w3.org/2001/XMLSchema#string

Issues in assessing products for the treatment of hemophilia - the intersection between efficacy, economics, and ethics.

about

P2860

P2860

Issues in assessing products for the treatment of hemophilia - the intersection between efficacy, economics, and ethics.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932